Galectin 3 complements BNP in risk stratification in acute heart failure

Gregory J. Fermann; Christopher J. Lindsell; Alan B. Storrow; Kimberly Hart; Matthew Sperling; Susan Roll; Neal L. Weintraub; Karen F. Miller; David J. Maron; Allen J. Naftilan; John A. McPherson; Douglas B. Sawyer; Robert Christenson; Sean P. Collins

doi:10.3109/1354750X.2012.719037

Galectin 3 complements BNP in risk stratification in acute heart failure

Gregory J. Fermann, Christopher J. Lindsell, Alan B. Storrow, Kimberly Hart, Matthew Sperling, Susan Roll, Neal L. Weintraub, Karen F. Miller, David J. Maron, Allen J. Naftilan, John A. McPherson, Douglas B. Sawyer, Robert Christenson, Sean P. Collins

Cardiology

Research output: Contribution to journal › Article › peer-review

48 Scopus citations

Abstract

Background: Galectin 3 (G3) is a mediator of fibrosis and remodeling in heart failure. Methods: Patients diagnosed with and treated for Acute Heart Failure Syndromes were prospectively enrolled in the Decision Making in Acute Decompensated Heart Failure multicenter trial. Results: Patients with a higher G3 had a history of renal disease, a lower heart rate and acute kidney injury. They also tended to have a history of HF and 30-day adverse events compared with B-type natriuretic peptide. Conclusion: In Acute Heart Failure Syndromes, G3 levels do not provide prognostic value, but when used complementary to B-type natriuretic peptide, G3 is associated with renal dysfunction and may predict 30-day events.

Original language	English (US)
Pages (from-to)	706-713
Number of pages	8
Journal	Biomarkers
Volume	17
Issue number	8
DOIs	https://doi.org/10.3109/1354750X.2012.719037
State	Published - Dec 2012

Keywords

Acute heart failure
Renal disease
Risk stratification

ASJC Scopus subject areas

Biochemistry
Clinical Biochemistry
Health, Toxicology and Mutagenesis

Access to Document

10.3109/1354750X.2012.719037

Cite this

@article{3f9c8c6629da43f9849a4f89ba233a98,

title = "Galectin 3 complements BNP in risk stratification in acute heart failure",

abstract = "Background: Galectin 3 (G3) is a mediator of fibrosis and remodeling in heart failure. Methods: Patients diagnosed with and treated for Acute Heart Failure Syndromes were prospectively enrolled in the Decision Making in Acute Decompensated Heart Failure multicenter trial. Results: Patients with a higher G3 had a history of renal disease, a lower heart rate and acute kidney injury. They also tended to have a history of HF and 30-day adverse events compared with B-type natriuretic peptide. Conclusion: In Acute Heart Failure Syndromes, G3 levels do not provide prognostic value, but when used complementary to B-type natriuretic peptide, G3 is associated with renal dysfunction and may predict 30-day events.",

keywords = "Acute heart failure, Renal disease, Risk stratification",

author = "Fermann, {Gregory J.} and Lindsell, {Christopher J.} and Storrow, {Alan B.} and Kimberly Hart and Matthew Sperling and Susan Roll and Weintraub, {Neal L.} and Miller, {Karen F.} and Maron, {David J.} and Naftilan, {Allen J.} and McPherson, {John A.} and Sawyer, {Douglas B.} and Robert Christenson and Collins, {Sean P.}",

note = "Funding Information: This was presented at the Society for Academic Emergency Medicine, Annual Meeting, 3 June 2011, Boston, MA, USA. This research was supported by a grant from Abbott Laboratories. Support for galectin-3 measurements provided by BG Medicine, Inc. (Waltham, MA). This study was supported in part by National Institute of Health Grant HL076684 to NLW. This work was supported in part by National Heart, Lung and Blood Institute grant K23HL085387 and an institutional Clinical and Translational Science Award NIH/NCRR Grant Number 1UL1RR026314-01.",

year = "2012",

month = dec,

doi = "10.3109/1354750X.2012.719037",

language = "English (US)",

volume = "17",

pages = "706--713",

journal = "Biomarkers",

issn = "1354-750X",

publisher = "Informa Healthcare",

number = "8",

}

TY - JOUR

T1 - Galectin 3 complements BNP in risk stratification in acute heart failure

AU - Fermann, Gregory J.

AU - Lindsell, Christopher J.

AU - Storrow, Alan B.

AU - Hart, Kimberly

AU - Sperling, Matthew

AU - Roll, Susan

AU - Weintraub, Neal L.

AU - Miller, Karen F.

AU - Maron, David J.

AU - Naftilan, Allen J.

AU - McPherson, John A.

AU - Sawyer, Douglas B.

AU - Christenson, Robert

AU - Collins, Sean P.

N1 - Funding Information: This was presented at the Society for Academic Emergency Medicine, Annual Meeting, 3 June 2011, Boston, MA, USA. This research was supported by a grant from Abbott Laboratories. Support for galectin-3 measurements provided by BG Medicine, Inc. (Waltham, MA). This study was supported in part by National Institute of Health Grant HL076684 to NLW. This work was supported in part by National Heart, Lung and Blood Institute grant K23HL085387 and an institutional Clinical and Translational Science Award NIH/NCRR Grant Number 1UL1RR026314-01.

PY - 2012/12

Y1 - 2012/12

N2 - Background: Galectin 3 (G3) is a mediator of fibrosis and remodeling in heart failure. Methods: Patients diagnosed with and treated for Acute Heart Failure Syndromes were prospectively enrolled in the Decision Making in Acute Decompensated Heart Failure multicenter trial. Results: Patients with a higher G3 had a history of renal disease, a lower heart rate and acute kidney injury. They also tended to have a history of HF and 30-day adverse events compared with B-type natriuretic peptide. Conclusion: In Acute Heart Failure Syndromes, G3 levels do not provide prognostic value, but when used complementary to B-type natriuretic peptide, G3 is associated with renal dysfunction and may predict 30-day events.

AB - Background: Galectin 3 (G3) is a mediator of fibrosis and remodeling in heart failure. Methods: Patients diagnosed with and treated for Acute Heart Failure Syndromes were prospectively enrolled in the Decision Making in Acute Decompensated Heart Failure multicenter trial. Results: Patients with a higher G3 had a history of renal disease, a lower heart rate and acute kidney injury. They also tended to have a history of HF and 30-day adverse events compared with B-type natriuretic peptide. Conclusion: In Acute Heart Failure Syndromes, G3 levels do not provide prognostic value, but when used complementary to B-type natriuretic peptide, G3 is associated with renal dysfunction and may predict 30-day events.

KW - Acute heart failure

KW - Renal disease

KW - Risk stratification

UR - http://www.scopus.com/inward/record.url?scp=84870482586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870482586&partnerID=8YFLogxK

U2 - 10.3109/1354750X.2012.719037

DO - 10.3109/1354750X.2012.719037

M3 - Article

C2 - 22998064

AN - SCOPUS:84870482586

SN - 1354-750X

VL - 17

SP - 706

EP - 713

JO - Biomarkers

JF - Biomarkers

IS - 8

ER -

Galectin 3 complements BNP in risk stratification in acute heart failure

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this